3-(2-吡啶基)苯胺 | 15889-32-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(2-吡啶基)苯胺
• 中文别名: 3-(2-吡啶基)苯胺盐酸盐
• 英文名称: 3-(2-pyridyl)aniline
• 英文别名: 2-(3-aminophenyl)pyridine；3-(pyridin-2-yl)aniline；2-(3-Amino-phenyl)-pyridin；3-pyridin-2-ylaniline
• CAS: 15889-32-4
• 化学式: C₁₁H₁₀N₂
• 分子量: 170.214
• InChiKey: YLNMGMIEOWFPRX-UHFFFAOYSA-N

物化性质

• 熔点：
  72-73℃
• 沸点：
  145-147 °C(Press: 0.1 Torr)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  | 室温 干燥 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(2-Pyridyl)aniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(2-Pyridyl)aniline
CAS number: 15889-32-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H10N2
Molecular weight: 170.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN2811 Class: 6.1 Packing group: III
Proper shipping name: TOXIC SOLIDS, ORGANIC, N.O.S. (3-(2-Pyridyl)aniline)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(2-吡啶基)苯胺 在 1,1'-双(二苯基膦)二茂铁 、 三叔丁基膦 、 palladium diacetate 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 48.0h， 生成 N,N-di(3-(pyridin-2-yl)phenyl)aniline
  参考文献：
  名称：

  [EN] LIGANDS AND THEIR PREPARATION
  [FR] LIGANDS ET LEUR PRÉPARATION

  摘要：

  本发明涉及适用于制备有机金属配合物配体的二级胺，其制备以及其用途。

  公开号：

  WO2014015936A1
• 作为产物：
  描述：

  2-苯基吡啶 在 硫酸 、 palladium on activated charcoal 、 氢气 、 potassium nitrate 作用下， 以 甲醇 为溶剂， 反应 5.0h， 生成 3-(2-吡啶基)苯胺
  参考文献：
  名称：

  通过 Ru3(CO)12 催化的邻位金属化策略对芳烃进行间位选择性 CAr-H 硝化

  摘要：

  描述了过渡金属催化芳烃间位选择性 CAr-H 硝化的第一个例子。以Ru3(CO)12为催化剂，以Cu(NO3)2·3H2O为硝基源，以间位选择性专门硝化了具有多种N-杂环或肟基作为导向基团的广谱芳烃。机理研究表明，形成了一种新的 18e-八面体钌物质作为关键的邻位 CAr-H 金属化中间体，这可能是随后的间选择性亲电芳香取代 (SEAr) 的原因。此外，这种方法为许多有用的药物分子的原子/分步经济合成提供了快速通道策略。

  DOI：

  10.1021/jacs.6b03402

文献信息

• Scope and selectivity in palladium-catalyzed directed C–H bond halogenation reactions
  作者：Dipannita Kalyani、Allison R. Dick、Waseem Q. Anani、Melanie S. Sanford

  DOI：10.1016/j.tet.2006.06.075

  日期：2006.12

  Palladium-catalyzed ligand directed C–H activation/halogenation reactions have been extensively explored. Both the nature of the directing group and the substitution pattern on the arene ring of the substrate lead to different reactivity profiles, and often different and complementary products, in the presence and absence of the catalyst.

  钯催化的配体定向的C–H活化/卤化反应已得到广泛研究。在存在和不存在催化剂的情况下，导向基团的性质和底物的芳环上的取代图案均导致不同的反应性分布，并且常常导致不同的和互补的产物。
• Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution
  作者：Thuy Nguyen、Nadezhda German、Ann M. Decker、Tiffany L. Langston、Thomas F. Gamage、Charlotte E. Farquhar、Jun-Xu Li、Jenny L. Wiley、Brian F. Thomas、Yanan Zhang

  DOI：10.1021/acs.jmedchem.7b00707

  日期：2017.9.14

  Allosteric modulators of the cannabinoid CB1 receptor have recently been reported as an alternative approach to modulate the CB1 receptor for therapeutic benefits. In this study, we report the design and synthesis of a series of diarylureas derived from PSNCBAM-1 (2). Similar to 2, these diarylureas dose-dependently inhibited CP55,940-induced intracellular calcium mobilization and [35S]GTP-γ-S binding

  最近有报道称，大麻素CB1受体的变构调节剂是调节CB1受体的另一种治疗方法。在这项研究中，我们报告了一系列源自PSNCBAM-1（2）的二芳基脲的设计和合成。与2相似，这些二芳基脲剂量依赖性地抑制CP55,940诱导的细胞内钙动员和[ 35 S]GTP-γ-S结合，同时增强[ 3 H] CP55,940与CB1受体的结合。结构-活性关系研究表明2的吡啶基环可以被其他芳族环取代，而CB1变构调节不需要吡咯烷基环。34（RTICBM-74）在所有体外测定中的功效均与2相似，但对大鼠肝微粒体的代谢稳定性显着提高。更重要的是，在减轻大鼠熄灭的可卡因寻求行为的恢复方面，34比2更有效，证明了该二芳基脲系列有潜力成为可卡因成瘾复发治疗发展的有希望的候选者。
• [EN] DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS<br/>[FR] DIARYLURÉES EN TANT QUE MODULATEURS ALLOSTÉRIQUES DE CB1
  申请人：RTI INT

  公开号：WO2018209030A1

  公开（公告）日：2018-11-15

  The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.

  本发明提供了新颖的二芳基脲衍生物（式（I）化合物）及其用途。本发明的化合物被证明是CB1受体的变构调节剂，因此对于治疗由CB1介导的疾病和症状是有用的。
• [EN] ARYL AND HETEROARYL COMPOUNDS, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF GALACTOCEREBROSIDASE<br/>[FR] COMPOSÉS ARYLE ET HÉTÉROARYLE, LEURS UTILISATIONS THÉRAPEUTIQUES DANS DES CONDITIONS ASSOCIÉES À L'ALTÉRATION DE L'ACTIVITÉ DE LA GALACTOCÉRÉBROSIDASE
  申请人：GAIN THERAPEUTICS SA

  公开号：WO2021105906A1

  公开（公告）日：2021-06-03

  The application is directed to compounds of formulae (IA) and (IB): (IA) and (IB), and their salts and solvates, wherein R1a, R2a, A1, A2, A3, A4, R1b, R2b, B1, B2, B3, and G are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Krabbe's disease, and α-synucleinopathies, such as Parkinson's disease.

  该申请涉及式(IA)和(IB)的化合物：(IA)和(IB)，以及它们的盐和溶剂化物，其中R1a，R2a，A1，A2，A3，A4，R1b，R2b，B1，B2，B3和G如说明书所述，还包括它们的制备方法、包含同一的药物组合物，以及用于治疗和/或预防例如溶酶体贮积病（如克拉伯病）和α-突触核蛋白opathies（如帕金森病）的用途。
• The two isomers of a cyclometallated palladium sensitizer show different photodynamic properties in cancer cells
  作者：Xue-Quan Zhou、Anja Busemann、Michael S. Meijer、Maxime A. Siegler、Sylvestre Bonnet

  DOI：10.1039/c8cc10134e

  日期：——

  position of the carbon–metal bond in a polypyridyl cyclopalladated complex, i.e. going from PdL1 (N^N^C^N) to PdL2 (N^N^N^C), dramatically influences the photodynamic properties of the complex in cancer cells. This effect is primarily attributed to the significantly difference in absorbance and singlet oxygen quantum yields between the two isomers.

  该报告表明，改变聚吡啶基环钯配合物中碳-金属键的位置，即从PdL 1（N ^ N ^ C ^ N）变为PdL 2（N ^ N ^ N ^ C），会极大地影响光动力学。复合物在癌细胞中的性质。该效应主要归因于两种异构体之间的吸光度和单重态氧量子产率的显着差异。